118 results
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
placement of equity securities.
Research and Development (R&D) expenses: R&D expenses totaled $34.9 million for the first quarter of 2024 and $13.8 … , except share and per share amounts)
Three Months Ended
March 31,
Revenue:
Development fee and royalty
Total revenue
Operating expenses:
Research
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
requires a substantial amount of capital. We expect our research and development expenses to increase in connection with our ongoing activities … or commercialization of our product candidates;
seek strategic partnerships, or amend existing partnerships, for research and development programs
POS AM
SYRE
Spyre Therapeutics Inc.
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
. We expect our research and development expenses to increase in connection with our ongoing activities, particularly as we advance our product … candidates;
seek strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise would
POS AM
c0rn4b41o j329
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
6u8 vfb1f
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.2
6hbbr msluzru7
15 Nov 23
Other Events
5:14pm
8-K
EX-99.1
15qfbpabwc4pnguobe
15 Nov 23
Other Events
5:14pm